We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Following >1,100 breast cancer survivors, PREVENT is the largest, multi-site randomized controlled trial (RCT) ever performed to study lymphedema prevention ImpediMed Limited...
ImpediMed Limited (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy...
Largest prospective, multi-center, randomized trial undertaken in the prevention of breast cancer-related lymphedema ImpediMed Limited (ASX:IPD), a global provider of medical technology...
Joins with medi, makers of compression products, to co-sponsor an invite-only reception “starring” Academy Award winner Kathy Bates, March 28 Supports Lymphatic Education &...
ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy...
Richard Carreon, managing director and CEO, accepts prestigious honor ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage...
International authority on lymphedema, Stanley G. Rockson, M.D., calls for use of Bioimpedance Spectroscopy as protocol in surveillance and assessment of cancer survivors Growing body...
Richard Carreon, managing director and CEO, to present at 19th Innovations in Healthcare Awards, Dec. 5, 2018, Long Beach Airport Marriott Hotel ImpediMed Limited (ASX: IPD), a...
Study concludes L-Dex correlates most closely with all measures and is the recommended metric when using BIS Publication of a new study to assess the validity of L-Dex bioimpedance...
ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0025 | -4.03225806452 | 0.062 | 0.063 | 0.058 | 587704 | 0.05889331 | DE |
4 | 0.0155 | 35.2272727273 | 0.044 | 0.065 | 0.043 | 1629266 | 0.05512443 | DE |
12 | -0.0045 | -7.03125 | 0.064 | 0.07 | 0.042 | 2108926 | 0.05390088 | DE |
26 | -0.0315 | -34.6153846154 | 0.091 | 0.105 | 0.042 | 1911145 | 0.0646517 | DE |
52 | -0.0905 | -60.3333333333 | 0.15 | 0.16 | 0.042 | 2234428 | 0.08834263 | DE |
156 | -0.0705 | -54.2307692308 | 0.13 | 0.24 | 0.042 | 2664810 | 0.12652507 | DE |
260 | -0.1105 | -65 | 0.17 | 0.24 | 0.032 | 2594335 | 0.11504073 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions